The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial.
 
Philippe Moreau
Honoraria - Abbvie; Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; Amgen; Celgene; GlaxoSmithKline; Janssen; Pfizer; Sanofi
 
Pieter Sonneveld
Leadership - European Myeloma Network
Consulting or Advisory Role - Amgen; CARsgen Therapeutics; Celgene; Janssen; Karyopharm Therapeutics
Research Funding - Amgen (Inst); BMS (Inst); Janssen (Inst); Skyline Diagnostics (Inst)
 
Hermann Einsele
Honoraria - Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Novartis; Sanofi; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Novartis; Sanofi; Takeda
Research Funding - Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Sanofi
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb/Celgene; Janssen; Novartis; Sanofi; Takeda
 
Hang Quach
Consulting or Advisory Role - Antengene (Inst); Bristol-Myers Squibb/Celgene; GlaxoSmithKline (Inst); Janssen-Cilag; Karyopharm Therapeutics (Inst); Pfizer; Roche; Sanofi (Inst)
Research Funding - Amgen; Bristol-Myers Squibb/Celgene; Celgene; GlaxoSmithKline; Karyopharm Therapeutics; Sanofi
 
P. Joy Ho
Research Funding - Janssen; Novartis
Travel, Accommodations, Expenses - Gilead Sciences
(OPTIONAL) Uncompensated Relationships - Advisory Board, honorarium not accepted: Gilead, GSK, Janssen, Pfizer, iTeos Therapeutics
 
Meral Beksac
Consulting or Advisory Role - BMS Turkey (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Oncopeptides (Inst); Pfizer (Inst); Sanofi (Inst); Takeda (Inst)
Speakers' Bureau - BMS Turkey (Inst); Menarini (Inst); Sanofi (Inst); Takeda (Inst)
 
Cyrille Hulin
Honoraria - Amgen; Bristol-Myers Squibb; Janssen; Sanofi
Travel, Accommodations, Expenses - Janssen; Pfizer; Sanofi
 
Elisabetta Antaonioli
Consulting or Advisory Role - GlaxoSmithKline; Johnson & Johnson; Pfizer
 
Xavier Leleu
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; GlaxoSmithKline; Janssen-Cilag; Novartis; Oncopeptides; Roche; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Janssen-Cilag; Novartis; Roche; Takeda
Travel, Accommodations, Expenses - Takeda
 
Silvia Mangiacavalli
Honoraria - Amgen; Celgene; GlaxoSmithKline; Janssen; Sanofi; Takeda
Consulting or Advisory Role - Amgen; Janssen; Takeda
 
Aurore Perrot
Honoraria - Abbvie; Amgen; BMS; GlaxoSmithKline; Janssen; Pfizer; Sanofi; Takeda
Research Funding - Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; Janssen
 
Michele Cavo
Honoraria - Abbvie; Adaptive Biotechnologies; Amgen; Celgene/Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Menarini Group; Sanofi; Takeda
Consulting or Advisory Role - Amgen, AbbVie, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Menarini Stemline, Sanofi, and Karyopharm Therapeutics
Speakers' Bureau - Celgene/Bristol-Myers Squibb; Janssen
 
Angelo Belotti
Consulting or Advisory Role - Amgen; GlaxoSmithKline; Janssen; Menarini Group; Pfizer; Sanofi
 
Annemiek Broijl
Honoraria - Amgen; Bristol-Myers Squibb; Janssen; Sanofi
 
Huiling Pei
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Jitsuda Sitthi-Amorn
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development; Roivant Sciences Ltd. (I)
 
Robin Carson
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Meletios Dimopoulos
Honoraria - Amgen; AstraZeneca; Beigene; Bristol-Myers Squibb; GlaxoSmithKline; Janssen-Cilag; Menarini; Regeneron; Sanofi; Swixx BioPharma; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Beigene; Bristol-Myers Squibb; GlaxoSmithKline; Janssen-Cilag; Menarini; Regeneron; Sanofi; Swixx BioPharma; Takeda
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb/Celgene; Janssen; Takeda
 
Paula Rodríguez-Otero
Honoraria - Abbvie; Celgene; GlaxoSmithKline; H3 Biomedicine; Janssen; Pfizer; Regeneron; Roche/Genentech; Sanofi
Consulting or Advisory Role - Abbvie; BMS; GlaxoSmithKline; Janssen; Pfizer; Roche; Sanofi
Speakers' Bureau - BMS; GlaxoSmithKline; Janssen; Sanofi
Travel, Accommodations, Expenses - Pfizer
 
Mario Boccadoro
Honoraria - AbbVie; Amgen; Bristol Myers Squibb; Celgene; Janssen; Novartis; Sanofi
Consulting or Advisory Role - GlaxoSmithKline; Janssen
Research Funding - Amgen (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Janssen (Inst); Mundipharma (Inst); Novartis (Inst); Sanofi (Inst)